NeoPhore signs research collaboration with The Institute of Cancer Research, London

London, UK, 18 April 2023, – NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces that it has signed a strategic collaboration agreement with Professor Chris Lord’s lab at The Institute of Cancer Research, London. The collaboration will use NeoPhore’s proprietary small molecule inhibitors of DNA mismatch repair (‘MMR’) to investigate single agent activity against tumours with defined genetic backgrounds.

Building on the seminal discoveries and ongoing research of its scientific founders and collaborators, NeoPhore is developing a pipeline targeting novel proteins in the DNA mismatch repair pathway to treat cancer. The Company’s first-in-class MMR modulators induce neoantigen expression and increase immunogenicity in solid tumours that become exquisitely sensitive to immunotherapy.

Read more…